86 related articles for article (PubMed ID: 19070808)
1. [Angiogenesis: the renal cancer model].
Méjean A; Lebret T
Prog Urol; 2008 Nov; 18 Suppl 7():S309-14. PubMed ID: 19070808
[TBL] [Abstract][Full Text] [Related]
2. [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].
Fergelot P; Rioux-Leclercq N; Patard JJ
Prog Urol; 2005 Dec; 15(6):1021-9. PubMed ID: 16429647
[TBL] [Abstract][Full Text] [Related]
3. Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
Ebbinghaus SW; Gordon MS
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1143-59, ix-x. PubMed ID: 15474339
[TBL] [Abstract][Full Text] [Related]
4. The role of vascular endothelial growth factor in kidney and prostate cancer.
Delongchamps NB; Peyromaure M
Can J Urol; 2007 Oct; 14(5):3669-77. PubMed ID: 17949520
[TBL] [Abstract][Full Text] [Related]
5. [Renal cell carcinoma and prognostic factors].
Edeline J; Rioux-Leclercq N
Ann Pathol; 2008 Oct; 28(5):374-80. PubMed ID: 19068392
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of renal cell carcinoma after hysterectomy: possible causes and implications.
Goldstein MR; Mascitelli L
Arch Intern Med; 2011 Jul; 171(13):1214-5; author reply 1215-6. PubMed ID: 21747022
[No Abstract] [Full Text] [Related]
7. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome.
Pollard P; Wortham N; Barclay E; Alam A; Elia G; Manek S; Poulsom R; Tomlinson I
J Pathol; 2005 Jan; 205(1):41-9. PubMed ID: 15586379
[TBL] [Abstract][Full Text] [Related]
8. The significance of angiogenesis and tumoral proliferation in renal cell carcinoma.
Puşcaşiu D; Tatu C; Tatu RF; Potencz E; Popescu R; Muntean I; Verdeş D
Rom J Morphol Embryol; 2011; 52(1 Suppl):369-72. PubMed ID: 21424076
[TBL] [Abstract][Full Text] [Related]
9. Effect of endothelial PAS domain protein 1 and hypoxia inducible factor 1alpha on vascular endothelial growth factor expression in human pancreatic carcinoma.
Zhu DM; Li DC; Zhang ZX; Zhang XY
Chin Med J (Engl); 2008 Nov; 121(22):2258-64. PubMed ID: 19080330
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma.
Cenni E; Perut F; Granchi D; Avnet S; Amato I; Brandi ML; Giunti A; Baldini N
Anticancer Res; 2007; 27(1A):315-9. PubMed ID: 17352248
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages.
Toge H; Inagaki T; Kojimoto Y; Shinka T; Hara I
Int J Urol; 2009 Oct; 16(10):801-7. PubMed ID: 19811548
[TBL] [Abstract][Full Text] [Related]
12. Serous neoplasms of the pancreas share many, but not all aspects of their microvascular and angiogenic profile with low-grade clear cell renal cell carcinomas.
Liszka Ł; Pająk J; Gołka D
Pathol Res Pract; 2014 Dec; 210(12):901-8. PubMed ID: 25155377
[TBL] [Abstract][Full Text] [Related]
13. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma.
Abrahamson PA
Eur Urol; 2006 Sep; 50(3):609-11. PubMed ID: 16824676
[No Abstract] [Full Text] [Related]
14. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
15. Complexity of tumor vasculature in clear cell renal cell carcinoma.
Qian CN; Huang D; Wondergem B; Teh BT
Cancer; 2009 May; 115(10 Suppl):2282-9. PubMed ID: 19402071
[TBL] [Abstract][Full Text] [Related]
16. [Renal cell carcinoma: the end of a tunnel?].
Ravaud A; Dilhuydy MS
Pathol Biol (Paris); 2006 May; 54(4):206-8. PubMed ID: 16530346
[No Abstract] [Full Text] [Related]
17. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Bran B; Bran G; Hörmann K; Riedel F
Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496
[TBL] [Abstract][Full Text] [Related]
18. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
[No Abstract] [Full Text] [Related]
19. Recipient origin of vasculature in renal cell carcinoma in a kidney allograft.
Hill PA
Pathology; 2010; 42(5):479-80. PubMed ID: 20632827
[No Abstract] [Full Text] [Related]
20. Correspondence re: E. Sabo et al., Microscopic Analysis and Significance of Vascular Architectural Complexity in Renal Cell Carcinoma. Clin. Cancer Res., 7: 533-537, 2001.
Grizzi F; Colombo P; Barbieri B; Franceschini B; Roncalli M; Chiriva-Internati M; Muzzio PC; Dioguardi N
Clin Cancer Res; 2001 Oct; 7(10):3305-7. PubMed ID: 11595729
[No Abstract] [Full Text] [Related]
[Next] [New Search]
